Cargando…

1-Hydroxyanthraquinones Containing Aryl Substituents as Potent and Selective Anticancer Agents

A series of 1,2-, 1,4-disubstituted or 1,2,4-trisubstituted anthraquinone-based compounds was designed, synthesized, characterized and biologically evaluated for anticancer efficacy. 2- or 4-arylated 1-hydroxy-9,10-antraquinones (anthracene-9,10-diones) were prepared by Suzuki–Miyaura cross-coupling...

Descripción completa

Detalles Bibliográficos
Autores principales: Sirazhetdinova, Nafisa S., Savelyev, Victor A., Frolova, Tatyana S., Baev, Dmitry S., Klimenko, Lyubov S., Chernikov, Ivan V., Oleshko, Olga S., Sarojan, Teresa A., Pokrovskii, Andrey G., Shults, Elvira E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321108/
https://www.ncbi.nlm.nih.gov/pubmed/32486108
http://dx.doi.org/10.3390/molecules25112547
_version_ 1783551388695920640
author Sirazhetdinova, Nafisa S.
Savelyev, Victor A.
Frolova, Tatyana S.
Baev, Dmitry S.
Klimenko, Lyubov S.
Chernikov, Ivan V.
Oleshko, Olga S.
Sarojan, Teresa A.
Pokrovskii, Andrey G.
Shults, Elvira E.
author_facet Sirazhetdinova, Nafisa S.
Savelyev, Victor A.
Frolova, Tatyana S.
Baev, Dmitry S.
Klimenko, Lyubov S.
Chernikov, Ivan V.
Oleshko, Olga S.
Sarojan, Teresa A.
Pokrovskii, Andrey G.
Shults, Elvira E.
author_sort Sirazhetdinova, Nafisa S.
collection PubMed
description A series of 1,2-, 1,4-disubstituted or 1,2,4-trisubstituted anthraquinone-based compounds was designed, synthesized, characterized and biologically evaluated for anticancer efficacy. 2- or 4-arylated 1-hydroxy-9,10-antraquinones (anthracene-9,10-diones) were prepared by Suzuki–Miyaura cross-coupling reaction of 1-hydroxy-2-bromoanthraquinone, 1-hydroxy-4-iodoanthraquinone or 1-hydroxy-2,4-dibromoanthraquinone with arylboronic acids. The cross-coupling reaction of 2,4-dibromo-9,10-anthraquinone with arylboronic acids provide a convenient approach to 2,4-bis arylated 1-hydroxyanthraquinones with a variety of aryl substituent in the 2 and 4 position. The cytotoxicity of new anthraquinone derivatives was evaluated using the conventional MTT assays. The data revealed that six of the aryl substituted compounds among the entire series 3, 15, 16, 25, 27, 28 were comparable potent with the commercially available reference drug doxorubicin on the human glioblastoma cells SNB-19, prostate cancer DU-145 or breast cancer cells MDA-MB-231 and were relatively safe towards human telomerase (h-TERT)immortalized lung fibroblasts cells. The results suggested that the in vitro antitumor activity of synthesized 2-aryl, 4-aryl- and 2,4-diaryl substituted 1-hydroxyanthraquinones depends on the nature of the substituent within the cyclic backbone. Docking interaction of 2-, 4-substituted and 2,4-disubstituted 1-hydroxyanthraquinones indicates intercalative mode of binding of compounds with DNA topoisomerase. The interaction with the DNA of 4-aryl-13, 15, 16 and 4-(furan-3-yl)-23 1-hydroxyanthraquinones was experimentally confirmed through a change in electroforetic mobility. Further experiments with 1-hydroxy-4-phenyl-anthraquinone 13 demonstrated that the compound induced cell cycle arrest at sub-G1 phase in DU-145 cells in the concentration 1.1 μM, which is probably achieved by inducing apoptosis. 4-Arylsubstituted 1-hydroxyanthraquinones 13 and 16 induced the enhancement of DNA synthesis on SNB19 cell lines.
format Online
Article
Text
id pubmed-7321108
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73211082020-07-06 1-Hydroxyanthraquinones Containing Aryl Substituents as Potent and Selective Anticancer Agents Sirazhetdinova, Nafisa S. Savelyev, Victor A. Frolova, Tatyana S. Baev, Dmitry S. Klimenko, Lyubov S. Chernikov, Ivan V. Oleshko, Olga S. Sarojan, Teresa A. Pokrovskii, Andrey G. Shults, Elvira E. Molecules Article A series of 1,2-, 1,4-disubstituted or 1,2,4-trisubstituted anthraquinone-based compounds was designed, synthesized, characterized and biologically evaluated for anticancer efficacy. 2- or 4-arylated 1-hydroxy-9,10-antraquinones (anthracene-9,10-diones) were prepared by Suzuki–Miyaura cross-coupling reaction of 1-hydroxy-2-bromoanthraquinone, 1-hydroxy-4-iodoanthraquinone or 1-hydroxy-2,4-dibromoanthraquinone with arylboronic acids. The cross-coupling reaction of 2,4-dibromo-9,10-anthraquinone with arylboronic acids provide a convenient approach to 2,4-bis arylated 1-hydroxyanthraquinones with a variety of aryl substituent in the 2 and 4 position. The cytotoxicity of new anthraquinone derivatives was evaluated using the conventional MTT assays. The data revealed that six of the aryl substituted compounds among the entire series 3, 15, 16, 25, 27, 28 were comparable potent with the commercially available reference drug doxorubicin on the human glioblastoma cells SNB-19, prostate cancer DU-145 or breast cancer cells MDA-MB-231 and were relatively safe towards human telomerase (h-TERT)immortalized lung fibroblasts cells. The results suggested that the in vitro antitumor activity of synthesized 2-aryl, 4-aryl- and 2,4-diaryl substituted 1-hydroxyanthraquinones depends on the nature of the substituent within the cyclic backbone. Docking interaction of 2-, 4-substituted and 2,4-disubstituted 1-hydroxyanthraquinones indicates intercalative mode of binding of compounds with DNA topoisomerase. The interaction with the DNA of 4-aryl-13, 15, 16 and 4-(furan-3-yl)-23 1-hydroxyanthraquinones was experimentally confirmed through a change in electroforetic mobility. Further experiments with 1-hydroxy-4-phenyl-anthraquinone 13 demonstrated that the compound induced cell cycle arrest at sub-G1 phase in DU-145 cells in the concentration 1.1 μM, which is probably achieved by inducing apoptosis. 4-Arylsubstituted 1-hydroxyanthraquinones 13 and 16 induced the enhancement of DNA synthesis on SNB19 cell lines. MDPI 2020-05-29 /pmc/articles/PMC7321108/ /pubmed/32486108 http://dx.doi.org/10.3390/molecules25112547 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sirazhetdinova, Nafisa S.
Savelyev, Victor A.
Frolova, Tatyana S.
Baev, Dmitry S.
Klimenko, Lyubov S.
Chernikov, Ivan V.
Oleshko, Olga S.
Sarojan, Teresa A.
Pokrovskii, Andrey G.
Shults, Elvira E.
1-Hydroxyanthraquinones Containing Aryl Substituents as Potent and Selective Anticancer Agents
title 1-Hydroxyanthraquinones Containing Aryl Substituents as Potent and Selective Anticancer Agents
title_full 1-Hydroxyanthraquinones Containing Aryl Substituents as Potent and Selective Anticancer Agents
title_fullStr 1-Hydroxyanthraquinones Containing Aryl Substituents as Potent and Selective Anticancer Agents
title_full_unstemmed 1-Hydroxyanthraquinones Containing Aryl Substituents as Potent and Selective Anticancer Agents
title_short 1-Hydroxyanthraquinones Containing Aryl Substituents as Potent and Selective Anticancer Agents
title_sort 1-hydroxyanthraquinones containing aryl substituents as potent and selective anticancer agents
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321108/
https://www.ncbi.nlm.nih.gov/pubmed/32486108
http://dx.doi.org/10.3390/molecules25112547
work_keys_str_mv AT sirazhetdinovanafisas 1hydroxyanthraquinonescontainingarylsubstituentsaspotentandselectiveanticanceragents
AT savelyevvictora 1hydroxyanthraquinonescontainingarylsubstituentsaspotentandselectiveanticanceragents
AT frolovatatyanas 1hydroxyanthraquinonescontainingarylsubstituentsaspotentandselectiveanticanceragents
AT baevdmitrys 1hydroxyanthraquinonescontainingarylsubstituentsaspotentandselectiveanticanceragents
AT klimenkolyubovs 1hydroxyanthraquinonescontainingarylsubstituentsaspotentandselectiveanticanceragents
AT chernikovivanv 1hydroxyanthraquinonescontainingarylsubstituentsaspotentandselectiveanticanceragents
AT oleshkoolgas 1hydroxyanthraquinonescontainingarylsubstituentsaspotentandselectiveanticanceragents
AT sarojanteresaa 1hydroxyanthraquinonescontainingarylsubstituentsaspotentandselectiveanticanceragents
AT pokrovskiiandreyg 1hydroxyanthraquinonescontainingarylsubstituentsaspotentandselectiveanticanceragents
AT shultselvirae 1hydroxyanthraquinonescontainingarylsubstituentsaspotentandselectiveanticanceragents